An open-label phase 1 study to investigate the safety and maximum tolerated dose of INNO-206 (Doxorubicin-6-Maleimidocaproyl Hydrazone; DOXO-EMCH) administered as a 30 minute infusion every 3 weeks in subjects with advanced solid tumors

Trial Profile

An open-label phase 1 study to investigate the safety and maximum tolerated dose of INNO-206 (Doxorubicin-6-Maleimidocaproyl Hydrazone; DOXO-EMCH) administered as a 30 minute infusion every 3 weeks in subjects with advanced solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Aldoxorubicin (Primary)
  • Indications Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 13 Oct 2014 Results published in the Cancer.
    • 05 May 2014 Results were presented in a CytRx Corporation media release.
    • 15 Nov 2012 Results presented at the Connective Tissue Oncology Society (CTOS) 17th Annual Meeting and published in a CytRx Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top